A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis

Brief description of study

A Randomized Double-blind Placebo-controlled study to determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients with well-compensated NASH Cirrhosis.


Clinical Study Identifier: s22-01477
Principal Investigator: Ira M. Jacobson.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.